Generic Name and Formulations:
Desonide 0.05%; crm.
Encore Dermatology, Inc.
Indications for TRIDESILON:
Apply thin film 2–4 times daily. Do not occlude. Reevaluate if no improvement after 2 weeks.
Treat infection if present or develop; discontinue until infection controlled. Systemic absorption increased by altered skin barrier, inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Do not use near eyes, or if hypersensitivity to corticosteroid, or pre-existing skin atrophy. Allergic contact dermatitis. Pregnancy (Cat.C). Nursing mothers.
Pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, burning, hypergylcemia, liver function abnormality; HPA axis suppression (esp. in children).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age